Allakos Inc. (ALLK)

Market Cap	107.21M
Revenue (ttm)	n/a
Net Income (ttm)	-178.75M
Shares Out	89.34M
EPS (ttm)	-2.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	474,427
Open	1.280
Previous Close	1.290
Day's Range	1.200 - 1.380
52-Week Range	0.540 - 3.360
Beta	0.91
Analysts	Hold
Price Target	1.67 (+39.17%)
Earnings Date	Nov 6, 2024

About ALLK

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 19, 2018
• Employees: 131
• Stock Exchange: NASDAQ
• Ticker Symbol: ALLK
• Website: https://www.allakos.com

Analyst Forecast

According to 4 analysts, the average rating for ALLK stock is "Hold." The 12-month stock price forecast is $1.67, which is an increase of 39.17% from the latest price.

Price Target

$1.67

(39.17% upside)

Analyst Consensus: Hold